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The prognosis of epilepsy
BRIDGET MACDONALD
Institute of Neurology and National Hospital for Neurology and Neurosurgery, University College
London, London, UK
The cardinal question for a person developing seizures is ‘What is the likelihood that they will go away?’
‘Prognosis’ refers to the possible outcomes of a disease and the frequency at which they can be expected to occur. Prognostic
factors may include demographic features, disease-specific indicators (e.g. seizure frequency, aetiology of epilepsy) or co-
morbidity. Such factors do not necessarily cause the outcome, but they are associated strongly with the outcome measured.
They are distinct from risk factors—which are associated with the initial development of the disorder.
Ideas about the outcome for epilepsy have been altered radically in the past century by study of its epidemiology. The
prognosis for epilepsy comprises a number of measurable end-points: the prediction of recurrence after a single unprovoked
seizure, the chance of remission after the diagnosis of epilepsy and the risk of premature death.
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1. RECURRENCE OF SEIZURES AFTER A
FIRST SEIZURE
The overall risk of recurrence after the first seizure is
an important aspect of prognosis. It should be borne in
mind that factors affecting recurrence will not neces-
sarily be the same as those leading to chronic epilepsy.
1.1. The rate of recurrence
Estimates vary for the risk of recurrence after a sin-
gle seizure—from 27% to 81%2–16. The different re-
sults may be explained by methodological variations
between studies13, 17.
The earlier after the initial seizure that patients are
enrolled into a study, the higher the reported rates of
recurrence. Late enrolment, studies in which there is
delay between first seizure and assessment, or retro-
spective design biases studies towards lower recur-
rence rates2, 3, 5, 8, 16, 18, 19, because most recurrences
occur within the first few weeks13 and the risk of
seizure recurrence falls with time9, 12, 17, 20.
As many as one-third of patients do not present
until they had had more than two seizures21 and so
would be excluded from some studies of seizure re-
currence5, 15. Patients with generalized tonic–clonic
seizures are likely to present earlier than those who
have partial seizures, which may also bias studies.
Another important consideration is the frame of the
study and selection bias. Studies based in EEG, neu-
rology or paediatric clinics are not based on the same
population as community-based ones—clinic-based
groups have more severe seizure disorders4, 6, 10, 12, 22.
Retrospective data will inevitably give a bias to-
wards more severe cases with recurrence. Two retro-
spective studies of recurrence after first seizure report
very different rates: Annegers et al.11 reported rates of
36% by 1 year and 56% by 5 years, compared with
81% overall by Goodridge and Shorvon7, 23.
The only prospectively designed, community-based
study of seizure recurrence is the NGPSE, which gave
an overall rate of seizure recurrence of 67% by 1 year
and 78% by 3 years13.
Single seizures have a lower incidence rate than
epilepsy, implying that most patients will have two or
more seizures. The alternative explanation—that sin-
gle seizures are a more infrequent and different entity
from epilepsy—does not seem biologically plausible.
1.2. Seizure recurrence after diagnosis of
epilepsy
One study of seizure recurrence has looked at recur-
rence after two unprovoked seizures24. It attempted
to avoid some of the above-mentioned biases by only
recruiting patients within 24 hours of a first seizure,
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but excluded patients who at first presentation could
be said to have seizures once a medical history was
taken. They report the recurrence rate after first seizure
as 33% (CL = 26, 40); among those who had a sec-
ond seizure there was a 57% (CL = 45, 70) chance
of having a third at 1 year and 73% (CL = 59, 87)
at 4 years. Although it is stated that no patients who
had a second seizure were lost to follow-up, no figure
is given for loss to follow-up between first and second
seizure, which makes interpretation difficult. In addi-
tion, its population is drawn from neurology patients
and EEG referrals. There is an excess of male subjects
who account for 70% of the group.
1.3. Factors affecting rate of recurrence
Several prognostic factors for recurrence have been
identified, but they are not without controversy.
Age of onset below 10 years22 or 16 years3, 4, 13, 25,
or over 65 years12, 13, 26, 27 has been correlated with re-
currence. This has not been replicated in other similar
studies6, 11, 14. Sex does not correlate with prognosis
for early recurrence6, 11.
Partial seizures are associated with poorer outcome
for recurrence4, 7, 9, 11, 13, 14, 25, although not all studies
examining seizure type have found this correlation6.
Nocturnal seizures12 and mixed seizure types22 have
also shown higher recurrence rates.
Aetiology also shows a correlation with prognosis;
congenital neurological deficits predict higher rates
of recurrence11, 13. Seizures after stroke seem rela-
tively benign; they are common, affecting 11.5% by
5 years, but half of these are single seizures from first
cerebrovascular episode in a prospective community-
based study28. Head injury may be associated with
a higher rate of recurrence, but was reported in a
study that had a low rate of recurrence overall and
it, together with other studies, fall within the range
of expected seizure recurrence29, 30. Remote causes
of epilepsy, which included conditions such as stroke
or tumour, increased the rate of recurrence—in the
Rochester study from 45% in idiopathic seizures to
77%4, 6, 11, 14, 16, 27, 31—although other studies, which
examined remote causes, either found that only tu-
mours increased the recurrence rate12 or did not find
an effect13. Abnormal neurological examination has
been correlated to recurrence8, 11.
Some underlying genetic syndromes entail a life-
long tendency to seizures, which may either respond to
medication—as in juvenile myoclonic epilepsy32 and
autosomal dominant temporal lobe epilepsy33—or not
respond—as in nocturnal temporal lobe epilepsy34;
others have a very benign prognosis. Less specifically,
a family history of seizure disorders increases the risk
of recurrence6.
The presence of an EEG abnormality is more con-
troversial, but some studies have identified this as a
risk factor for recurrence5, 6, 8, 11, 14, 16, 26, 31, 35, 36.
These factors reflect the heterogeneity underlying
the diagnosis of ‘epilepsy’ and imply that a differing
case mix will influence reported recurrence rates.
1.4. Effect of medication on recurrence after a
first seizure
In most epidemiological studies of epilepsy, the de-
scriptive design does not influence the prescription
of antiepileptic medication. This means that patients
whose seizures are deemed to be more severe—in ei-
ther seizure type or underlying aetiology—are more
likely to be treated. This biases the results. Descriptive
studies have found that the risk of seizure recurrence
is not altered by medication6, 11, 14, 25, but studies have
reported a reduced chance of recurrence9, 12.
The only study that examines this appropriately, in
the context of a placebo-controlled trial of antiepilep-
tic drugs after a first seizure, found a threefold in-
creased risk of seizure recurrence in the untreated
group by 2 years26, 27. There are some reservations
about this study’s design—it excluded patients with
previous seizures and examined only generalized
seizures.
2. THE REMISSION OF EPILEPSY
Remission of epilepsy is the seizure-free period expe-
rienced by a patient who has had one or more seizures.
It is usually defined as being of 1–5 years’ duration.
Terminal remission is when the remission continues
to the end of follow-up. There are various factors that
influence the likelihood of achieving and maintaining
remission.
2.1. Methodological considerations
The interpretation of epidemiological studies requires
an appreciation of potential pitfalls in study design.
2.1.1. Definition and classification of epilepsy
By convention, the diagnosis of epilepsy is made only
after a second unprovoked seizure. Seizures can be the
symptomatic expression of a wide range of conditions
and, for this reason, the use of the term ‘the epilepsies’
is more appropriate than ‘epilepsy’37. Single, acute,
symptomatic seizures and febrile convulsions are not
considered to be epilepsy.
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The study of the prognosis of epilepsy is con-
founded by the diversity of underlying diagnoses; it is
in fact the prognosis of a diverse group of conditions of
known aetiologies or cryptogenic origin. In addition to
the differing risks for the underlying conditions, there
are the risks of the seizures themselves.
2.1.2. The difficulty of diagnosis
The case definition of epilepsy is deceptively clear-
cut: ‘two or more unprovoked epileptic seizures’. A
key difficulty is diagnosing the seizure. Seizures are
brief, pleomorphic—albeit often stereotypical in an
individual—and unpredictable. The diagnosis is based
on the history of the episodes, with some support from
investigations. The witnessed account, even when it is
available, may be difficult to interpret for many rea-
sons, among which poor observation or capacity to
describe the seizure and inaccuracy of second-hand
accounts are common sources of error. In addition,
there is variability in how clinicians interpret the in-
formation. This leads to diagnostic variation; for ex-
ample, in some reports 20% of patients referred to
specialist epilepsy clinics are diagnosed as not having
epilepsy38, 39. Interobserver reliability has been found
to be as low as a kappa value of 0.58 in one study15.
In the Rochester study, time from first seizure to di-
agnosis took over 6 months in 50% of patients and
over 2 years in 30%40. This lag time means that, when
studies exclude patients without a definite diagnosis,
considerable bias occurs; certain groups will be ex-
cluded more than others—elderly people, those with
learning difficulties, those with infrequent or noctur-
nal seizures—as all these patients are less likely to be
able to provide a clear account of the seizure. Most
studies, except the NGPSE, do not address this impor-
tant clinical issue4, 5, 7, 11.
Adding to the difficulty of diagnosis are other parox-
ysmal conditions, the presentation of which may be
confounded with epileptic seizures, such as syncope,
vertigo, panic disorders, hyperventilation syndrome41.
No investigation is definitive or highly reliable in the
diagnosis of seizure disorders.
Seizures that occur during a metabolic disturbance
or an acute illness are not considered as epilepsy be-
cause they are deemed to be caused by a pathological
process, which, because of its transient nature, cannot
be assumed to provoke further seizures; as a result, a
continuing tendency to seizure activity will not occur.
The distinction is, however, conventional and not the
result of a clear-cut physiological demarcation.
The difficulty in diagnosis remains throughout the
course of epilepsy; thus, non-epileptic seizures will in-
flate the figures for chronic epilepsy although it can be
difficult to estimate how much they contribute to the
20–30% of patients who will suffer chronically42.
Clearly, it is important that studies take the issue of
diagnosis seriously, so that comparison of results may
be made.
2.1.3. Difficulty in classification of epilepsy
A comprehensive syndromic classification was com-
missioned by the ILAE41. It was drawn up with the
intention of having a reliable clinical tool for the clas-
sification of epilepsy and to allow comparison between
studies. However, it may be difficult to apply; one
study that assessed its reliability found that this was
only 50%.
In attempting to classify epilepsy, some syndromes
are clear-cut, e.g. juvenile myoclonic epilepsy; how-
ever, despite extensive investigation and prolonged
follow-up, many patients remain difficult to classify
and, in addition, several aetiologies may underlie what
is the ‘same’ epileptic syndrome.
Moreover, the early remission of most epilepsies al-
lows little time for observation and investigation of the
active disorder. In most reliable studies, only half of
the cases are classified. In children, this poses greater
problems and one way of handling data is to group
‘disputable events’ separately—when using such a de-
marcation it was found that these children had a 10%
chance of seizure recurrence versus 54% overall16.
2.1.4. Population characteristics
Only community-based studies provide the full
breadth of the epilepsies because some patients may
never be referred for specialist opinion and the choice
of specialist is wide43, 44. Clinic-based studies are in-
fluenced by referral patterns, patient characteristics
and seizure severity; however, many studies are clinic
based9, 22, 45–53.
The community studied will also influence findings.
In Rochester, USA the population is homogeneous,
white, relatively affluent and of northern European de-
scent40, 54, 55.
2.1.5. Criteria for inclusion and exclusion
The criteria for inclusion and exclusion will affect
outcome measures. The exclusion of patients who
experience early recurrence seems likely to improve
the overall prognosis. When single seizures are ex-
cluded, those patients with a lower tendency to re-
cur are left out and remission rates are likely to be
lower21, 40, 55, 56. Similarly, an atypical population with
more severe seizures is selected if only patients tak-
ing AEDs are included50. Another bias that is difficult
to interpret is added if only patients who have had an
EEG are included57. In one study, FCs were not ex-
cluded but lumped together with other seizure types58.
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Some studies exclude patients with abnormal neurol-
ogy before the seizure47.
2.1.6. Temporal aspects
A turning point in the understanding of the natural his-
tory of seizure disorders came with the appreciation
that patients should be followed from the same point in
their illness—whether this is a first or second seizure,
or first presentation. If this is not done, there is a ten-
dency to find poor outcome because of the inclusion
in the cohort of those with ongoing seizures and more
severe epilepsy37, 59, 60. This underlies the poor prog-
nosis of epilepsy reported in older studies61, 62.
Most patients, if they are going to remit, go into re-
mission early in the course of their illness. For exam-
ple, in the Rochester study the net probability of enter-
ing remission was 65% over 10 years but, if remission
had not been achieved by 5 years, the chance of sub-
sequent remission was only 35%55.
2.1.7. Definition of remission
Different definitions of remission lead to difficulty
comparing studies. The time in remission varies
from 1 to 5 years16, 40, 49, 63. Whether any seizure-free
period is included as remission or only counted if it
is terminal remission7, 23, and whether AED status is
considered, are other sources of variability40, 55.
Generally, AED status is not considered as part of
the definition of remission, and many studies report
both terminal and non-terminal remission rates.
2.1.8. Prospective design
Prospective studies yield better data because they can
avoid bias by careful study design; information is
available that may not have been recorded meticu-
lously in normal clinical practice. This needs greater
resources.
Length of follow-up is central to the prognosis of
a chronic relapsing and remitting condition, and the
further back a retrospective study delves the more
bias must enter the study. Some of the Rochester data
go back to 193555; this is the same year that Faxe´n
wrote a critique of the definition of epilepsy, which
seems so far removed from current concepts of seizure
disorders59.
2.1.9. Length of follow-up
In a chronic disorder, the length of follow-up influ-
ences the remission rate. Studies of newly diagnosed
patients followed for 1 or 2 years give high remission
rates—of the order of 80%16, 22, 64. However, remis-
sion is only meaningful if the remission is lengthy and
hence the follow-up must be prolonged. Prospectively
designed studies are now reporting decades of follow-
up data55, 65, 66.
2.1.10. Loss to follow-up
Loss to follow-up can damage the validity of a study
because it cannot be assumed that those lost are iden-
tical or even similar to the rest of the group. Despite
the statistical tenet that the non-responders do not re-
semble the responders, many groups have just ignored
this problem63.
An alternative way of handling those lost to follow-
up in actuarial analysis is to assume that they have not
remitted, which will decrease remission rates and give
a pessimistic view of outcome.
2.1.11. Statistical analysis
Early in the course of their epilepsy, most patients will
remit; fewer remit with the passage of time. For this
reason, it is inappropriate to give the proportion of
patients going into remission if the cohort is not be-
ing followed from the same point in the illness.
Life-table analysis can handle only a single end-
point but, in epilepsy, patients may go in and out of
remission and may therefore need more sophisticated
statistical analysis. If both cumulative and terminal re-
mission are calculated, this can, to some extent, be ac-
counted for. As only 12% of patients have this inter-
mittent pattern, the bias may not be excessive7.
In the statistical analysis of prognostic factors, the
use of univariate analysis has confounded many stud-
ies. Unifactorial models are not appropriate for multi-
factorial disease. Coupled with the cut-off for statisti-
cal analysis of P < 0.05, which means that 1 in 20
factors is found to be significant by chance alone, in-
evitably studies will not always agree.
2.1.12. The effect of treatment on remission
The effect of treatment on epilepsy has been a con-
founder in many studies of the condition. When study-
ing a condition, ideally one would want an unbiased
set of factors acting on the whole cohort. If treatment
is being used, as indeed it is in every modern descrip-
tive study, this should be in a randomized fashion.
Interventional studies have demonstrated that most
patients presenting with epilepsy entered long-term
remission when treated10, 22, 50, 67–71. The studies that
found a good prognosis for patients presenting with
seizures were interpreted as causal—good prognosis
was seen as a product of appropriate early interven-
tion. Although it was argued by most authors at that
time that treatment improved prognosis there is little
evidence to uphold this view, and gathering evidence
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from interventional and epidemiological studies to re-
fute it.
A recent study examining the effect of treating
patients after their first or subsequent generalized
tonic–clonic seizures has shown no difference in long-
term (1 or 2 year) remission rates27.
Drug withdrawal is an important cause of seizure re-
lapse72.
2.2. Natural history
To study remission it is important to consider the nat-
ural history of the untreated condition. Epilepsy has
had effective treatments since bromide salts were used
in the 1850s, and so it has been difficult to study drug-
naı¨ve patients. The untreated patients in cohorts are
unlikely to be similar to the treated patients and often
have milder seizures73.
2.2.1. Studies in developing countries
In conditions showing no remission and long sur-
vival, lifetime prevalence rates will approach preva-
lence rates, the difference being attributable to differ-
ential deaths caused by the condition or its compli-
cations. In the developed countries, the difference be-
tween these rates has been attributed to drug-induced
remission. There is evidence that the incidence rates
of epilepsy in the developing world are higher mainly
as the result of acute bacterial infection, chronic viral
and parasitic infection, poor neonatal outcome and ac-
cidents37, 74. Prevalence rates should be higher in de-
veloping countries (allowing for related mortality) if
the notion that failure to provide early treatment for
epilepsy promoted chronicity and intractability was
true. However, large studies of the epidemiology of
epilepsy in these countries have reported rates that
are very similar to those in the developed world75, 76.
There are exceptions to this, but these studies are in
groups that have high rates of inherited neurodegener-
ative disorders, such as the Wapogoro of Tanzania and
residents of Gran Bassau county, Liberia77–81.
In Ecuador, a population-based study found a cu-
mulative incidence rate of 1.9% among a population
of 75 000, the prevalence rate of active epilepsy be-
ing 0.7%, which implies a remission rate of at least
50%82. Similar observations were made in a smaller
study from Malawi83. This supports the idea that spon-
taneous remission may occur37.
An additional argument against the development
of intractability is that studies have shown good
response rates for treatment initiated in unselected
drug-naı¨ve patients after many years of active
epilepsy51, 77, 78, 84, 85.
2.3. Overall remission rates from hospital-based
studies
2.3.1. Retrospective studies
Despite the biases discussed above, there have been
a large number of studies in recent decades that are
clinic based and retrospective. The Japanese group
have examined the outcome of seizures among 1868
patients seen in 20 clinics. Follow-up was problematic
because these patients constituted only 42% of those
who had attended these clinics during the frame of the
study. The remission rates for 3, 5 and 10 years were
around 58%86. In Aarhus, Denmark, a study of re-
mission in 1505 patients registered at diagnosis found
that 47% of patients with primary generalized epilepsy
were in remission compared with 28% of those with
complex partial seizures; these were crude percentages
without a long follow-up87.
2.3.2. Studies of newly diagnosed patients
Studies in clinic-based populations have reported
the effect of treatment among newly diagnosed
patients50, 64, 67, 69, 71, 88–91. Despite some differences
in their case ascertainment, they discuss the outcome
in terms of remission of seizures of 1, 2 or 5 years. The
reported 1-year remission rates vary between 58% and
95%, most falling between 65% and 80%16.
There is less unanimity over what features pre-
dict poorer outcomes. Partial seizures are thought to
have a worse prognosis for seizure control than gen-
eralized seizures (whether from generalized epilepsy
or in patients with secondarily generalized seizures
only)71. Multiple seizure types have also been linked
with worse prognosis, as have associated neurolog-
ical deficits and behavioural or psychiatric distur-
bance22, 50. A poorer outcome has been reported in
those who had experienced a high-frequency tonic–
clonic seizure before receiving any treatment10, 50. In
one study, there was a worse prognosis if there was a
family history of epilepsy10.
There are only clinic-based studies for prognosis of
specific epilepsy syndromes. Benign partial epilepsy
with centrotemporal spikes has a very good progno-
sis and practically all patients remit by puberty92, 93.
In contrast, typical absence epilepsy has a worse prog-
nosis than was previously believed and two-thirds of
patients remit16, 94, 95.
2.4. Population-based studies of remission
Retrospective studies have also described the remis-
sion of seizures in patients diagnosed with epilepsy
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and started on antiepileptic medication at some point
in the past.
In the UK, patients with chronic grand mal epilepsy
were surveyed and 42% had no seizures during that
year43.
In the Rochester study, remission was defined as
5 years without seizures; at a year after diagnosis, 42%
had entered into a period of remission and at 10 years
65% were in remission; at 15 years 76% were in a 5-
year remission40, 55.
The Tonbridge general practice study, in which
remission was defined as a 2-year period without
seizures, showed similarly that 73% of patients overall
were in remission7, 23.
In both Rochester and Tonbridge, most of the
patients who entered into remission had done so by
the end of the first 2 years. Thus, as time passed from
diagnosis, the chance of treated active epilepsy remit-
ting diminished.
2.5. Drug-withdrawal studies
As 70–80% of patients on AEDs become seizure free,
it is common clinical practice to consider withdrawal
once a patient has been in remission for a ‘reasonable’
length of time. A number of studies address this is-
sue58, 87, 91, 96–105. The range of probability of relapse
has varied from 11% to 41%. Studies of childhood
epilepsies fall into the bottom end of this range and
adult studies towards the upper end of the range. The
rate of relapse is highest in the early months after with-
drawal97, 102, 103.
There is considerable variation in methodology.
Older studies considered a reasonable seizure-free pe-
riod or minimum treatment time to be up to 5 years100.
More recent studies tend to consider shorter peri-
ods104, 105. A prospective comparison of prognosis
in children undergoing AED withdrawal after 6 or
12 months of seizure freedom found no difference
in outcome98, 100, 105. Exclusion criteria have varied;
some investigators considered it unreasonable to with-
draw medication if either the EEG had not returned to
normal102 or the patient had a neurological deficit103.
Patients whose seizures relapsed during the with-
drawal period, rather than after complete withdrawal,
were excluded from analysis in one study103.
The study that is not only the largest but also the best
designed72, 104 found a risk of relapse of 41% within
2 years of drug withdrawal, compared with a rate of
22% among the group randomized to continuing with
medication. This divergence between relapse rates was
maximal between 1 and 2 years, after this, the risk of
relapse was higher in those ‘remaining on treatment’.
This counterintuitive finding is most probably the re-
sult of the decision of patients, with or without medical
supervision, to stop their medication, but because this
is an assumption it needs to be treated circumspectly.
It would appear, however, that a substantial number of
patients are in remission and will remain so without
AEDs, whereas another group depend on their medi-
cation for seizure control.
It may be useful to examine not only the course of
the drug withdrawal in such patients, but also how this
relates to initial seizures and response to AEDs106.
Drug-withdrawal studies have found the following
factors related to poor outcome:
• total number of seizures87, 107,
• short seizure-free period72, 103, 104,
• seizures after starting antiepileptic medica-
tion58, 100, 104, 108,
• polytherapy72, 102–104,
• duration of treatment109,
• generalized tonic–clonic seizures72, 100, 104,
• myoclonus72, 104,
• partial seizures58, 72, 105, 109, 110,
• multiple seizure types58, 100,
• an abnormal EEG97, 98, 103–105, 107–109, 111, 112,
• symptomatic epilepsy52, 58, 97, 100, 103, 105, 108,
• previous FCs98,
• withdrawal of medication in adolescence97,
• none of these99.
2.6. Factors affecting prognosis for remission
2.6.1. Age
The effect of age on prognosis appears to follow a J-
shaped curve. Most studies have found that early onset
has a better prognosis than later-onset epilepsy40, 55, 57.
However, studies that have included enough children
show that prognosis is worse if epilepsy starts in the
first year or two of life17, reducing the 4-year remis-
sion rate from 69% to 47% in one study107.
There is an interaction between aetiology and age in
young-onset epilepsy—children with spastic quadri-
paresis accounted for 75% of children whose onset
of epilepsy was under 2 years—a lower age of onset
than in control epilepsy groups53; similarly infantile
spasms start before 1 year and have a particularly poor
prognosis (in one study only 16% were alive without
sequelae48). On the other hand, some of the benign
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epilepsies of childhood start later, such as benign par-
tial epilepsy with centrotemporal spikes, where the on-
set is between 3 years and puberty, or absence epilepsy
starting at around age 6–8 years.
2.6.2. Seizure type
It is generally held that seizure type has a strong ef-
fect on prognosis; however, a close examination of the
literature reveals that studies do not classify seizures
in a way that allows easy comparison and, in addition,
some findings are contradictory.
Partial seizures are thought to have a worse prog-
nosis for seizure control than generalized seizures
(whether from generalized epilepsy or in patients with
secondarily generalized seizures only)4, 66, 71, 75, 98, 110.
The following have also been linked with worse prog-
nosis:
• multiple seizure types49, 50, 58,
• atonic seizures66,
• infantile spasms17,
• generalized tonic–clonic seizures57,
• status epilepticus4, 113, 114.
Some studies have not found seizure type to be helpful
for prognostication63, 115.
2.6.3. Aetiology
Unlike clinic-based or retrospective stud-
ies47, 57, 86, 116, 117, it has been shown that there is little
difference in prognosis between idiopathic epilepsy
and symptomatic epilepsies in prospectively de-
signed, community-based studies7, 23. For example,
in Rochester, USA 74% of patients with idiopathic
epilepsy entered 5-year remission, which was not sig-
nificantly different from the symptomatic group55.
In this study, however, the subgroup of symptomatic
epilepsy who had congenital neurological dysfunction
did far worse and only 46% had entered remission
at 20 years. The finding that remote symptomatic
seizures in young children do worse than idiopathic
seizures in children is supported by a number of other
studies17, 49, 66, 113.
2.6.4. Electroencephalographic findings
The study of the importance of EEG abnormality has
been hampered by the clinic-based nature of the in-
vestigation, limiting the extrapolation of findings to
the community. For example, in the large community-
based cohort from Rochester, where there is ready ac-
cess to medical investigations, 71% had had an EEG;
it is reasonable to believe that those who were not in-
vestigated differed from the rest of the group57.
The association of different types of abnormali-
ties in specified subgroups has been correlated with
poor prognosis for remission, i.e. generalized activity
on the EEG in patients with generalized tonic–clonic
seizures57, abnormal background or paroxysmal activ-
ity in complex partial seizures47, paroxysmal frontal or
anterior temporal regions86, among others. However,
not all studies show an effect63, 118.
Another limiting factor in studies of EEG abnor-
mality and prognosis for remission is that some stud-
ies based inclusion criteria on the results of the
EEG46, 57, 75.
2.6.5. Early seizure pattern and its effect on
subsequent remission
The temporal pattern of epilepsy has been neglected.
There are only two reported studies7, 23, 119. One de-
scribed the pattern of seizures in 181 patients with
chronic epilepsy who attended an epilepsy clinic, and
the other of 180 patients identified in the community.
These groups were comparable in terms of age and
length of history. Three patterns of epilepsy were de-
scribed: a burst pattern (seizures at outset with early
prolonged remission), intermittent (as for burst pat-
tern, although after a remission of at least 2 years
there was a relapse) and continuous seizures from out-
set. The burst pattern accounted for 65% of cases in
the community, 25% having continuous epilepsy from
the outset, and 12% had remission followed by re-
lapse. This contrasted with those attending the special-
ist clinic, where only 22% had ever experienced a re-
mission at any stage in their condition7, 23. Thus, the
statement that epilepsy is a chronic remitting and re-
lapsing condition can be applied only to a minority of
patients who have seizures.
A separate issue is whether number or frequency of
seizures at the onset of the disorder is predictive of re-
mission. A worse prognosis has been reported in those
who experienced high-frequency tonic–clonic seizures
before receiving any treatment10, 22, 50, 120, or without
reference to medication49, 66, 69, 113, 121.
2.6.6. Other prognostic factors
A family history of epilepsy has been correlated with
a worse prognosis10, 69, but this was not found in other
studies63.
3. MORTALITY FROM EPILEPSY
There is an increased mortality rate among patients
with epilepsy. This has a peak in the first year af-
ter diagnosis as a result of those causes of epilepsy
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that have high case fatality, such as secondary brain
tumours, subarachnoid haemorrhage and stroke122.
However, the mortality rate remains elevated, particu-
larly among young adults with severe active epilepsy.
This finding is consistent in many studies. Mortality
is particularly high in those with cryptogenic seizures,
and idiopathic epilepsy and severe active epilepsy;
however, the standardized mortality ratio (SMR) for
patients whose seizures are in remission is also high at
around 1.8123–125.
Demographic features are important; men have
higher SMRs than women with epilepsy, especially
in those aged up to 40 years where death as a result
of other causes is infrequent. Among the over-75s, in
whom the death rate is high, the added risk of epilepsy
is much smaller.
Seizure type is important: absence seizures in iso-
lation display no excess mortality, whereas myoclonic
seizures have an SMR of 4.1124.
The most common causes of death among those
with epilepsy are chest infections, neoplasia, and
epilepsy-related deaths and accidents. Bronchopneu-
monia is the most common cause of increased SMR in
this group, with a rate of 1.7–7.9124, 126, 127. It has been
postulated that this is because of peri-ictal aspiration.
Tumours, with or without the inclusion of
brain tumours, are more frequent in patients with
epilepsy123, 124, 127. However this seems to be
caused by cancer diagnosed before the diagnosis of
epilepsy124, 126.
Epilepsy-related deaths are divided into those
caused by status epilepticus, sudden unexpected
death (SUDEP) or accidents. It has been postulated
that death associated with a seizure is the result of
autonomic instability, including apnoea, bradycardia
and cardiac arrhythmia, which can be recorded during
seizures128. The difference between seizure-related
death and SUDEP is that, in the former, the seizure is
witnessed; in the latter, a patient with epilepsy is found
dead and there is no cause found post mortem. The an-
nual incidence of SUDEP in an outpatient cohort of a
specialist epilepsy service was 1 in 200 patients with
chronic epilepsy129.
SMRs for accidents and trauma are raised. Suicide
is increased among those with epilepsy, especially if
severe, of relatively recent onset and arising in the
temporal lobe126. The NGPSE cohort has not demon-
strated this as a cause of excess mortality, despite the
inclusion of people whose epilepsy falls into these
categories122.
CONCLUSION
There is debate about why some patients achieve re-
mission and others do not. It has been suggested that
the failure to control seizures early on in the ill-
ness renders the epilepsy more resistant to treatment
in the future, perhaps because of secondary struc-
tural changes within the brain61, 69, 130–133. However,
an equally consistent explanation would be that the
epilepsy in any individual patient has an inherent
‘treatability’, and that severely affected patients will
be difficult to control from very early in their condi-
tion37, 73, 134–136. The only way of clarifying whether
early treatment has an impact on future prognosis is to
carry out a randomized trial; it was recently reported
that there was no improvement in long-term outcome
with treatment after first, compared with later, gener-
alized tonic–clonic seizures27.
There remain questions and controversies regard-
ing the prognosis for remission in the epilepsies; and
importantly these include the effect of aetiology and
syndromic classification on the prognosis of epilepsy
(community based to avoid the severity bias of clinic-
based studies), and the effect of treatment on prognosis
for remission137.
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